The therapeutic potential of targeting the cell cycle

Expert Opinion on Investigational Drugs

Volumn 7, Issue 6, 1998, Pages 865-887

  Webster, K R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Butyrolactone I; Cancer therapy; Cdk; Cell cycle; CVT 313; Cyclin; Cyclin dependent kinase; Flavopiridol; Olomoucine; Roscovitine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; OLOMOUCINE; PROTEIN P53; ROSCOVITINE; STAUROSPORINE; SURAMIN; TAUTOMYCIN; TOYOCAMYCIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; ENZYME INHIBITION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; REVIEW;

EID: 0031809781     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.6.865     Document Type: Review

References (213)